Filing Analysis
MariMed Inc. filed an 8-K to announce the issuance of a press release containing financial results for the three- and nine-month periods ended September 30, 2024.
📋 Key Facts
- Report date: November 6, 2024
- Reporting period: Three and nine months ended September 30, 2024
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition)
- Company is an emerging growth company
MariMed Inc. announced the appointment of Mario Pinho as Chief Financial Officer, effective August 9, 2024. He replaces Jon Levine in the CFO role, though Mr. Levine will remain with the company as President and CEO.
🚩 Red Flags
- None identified in this specific filing.
📋 Key Facts
- Mario Pinho appointed as CFO effective August 9, 2024.
- Jon Levine transitions from Interim CFO to focus on his roles as President and CEO.
- Pinho received an inducement award of 300,000 restricted stock units (RSUs).
- Annual base compensation for Pinho is set at $265,000 with a 30% performance bonus eligibility.
- Pinho brings significant experience from Rakuten USA, American Express, and KPMG LLP.
MariMed Inc. filed an 8-K to announce the release of its financial results for the three-month and six-month periods ended June 30, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly/semi-annual financial results (Item 2.02).
- Reporting period covers ends on June 30, 2024.
- Jon R. Levine serves as President, CEO, and Interim CFO.
MariMed Inc. held its 2024 Annual Meeting of Stockholders on June 6, 2024. The meeting resulted in the re-election of five directors and the advisory approval of M&K CPAs PLLC as independent auditors for the 2024 fiscal year.
📋 Key Facts
- Annual Meeting held on June 6, 2024.
- Five directors (Jon R. Levine, Edward Gildea, David Allen, Eva Selhub, M.D., and Kathleen Tucker) were re-elected to serve until the next annual meeting or successors are elected.
- Stockholders approved, on an advisory basis, the appointment of M&K CPAs PLLC as independent auditors for fiscal year 2024 with 205,177,744 votes in favor.
MariMed Inc. filed an 8-K to announce the release of its financial results for the three-month period ended March 31, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Reporting period: Three months ended March 31, 2024.
- Date of report/event: May 8, 2024.
- The company is classified as an 'emerging growth company'.
MariMed Inc. filed an 8-K to announce the release of its financial results for the three months and fiscal year ended December 31, 2023.
🚩 Red Flags
- Interim CFO role suggests potential recent turnover or instability in financial leadership (though not explicitly detailed in this specific 8-K text).
📋 Key Facts
- The filing is a standard announcement of quarterly and annual financial results (Item 2.02).
- Reporting period covers the three months and full year ended December 31, 2023.
- The company is classified as an 'emerging growth company'.
- Jon R. Levine serves as both President, CEO, and Interim CFO.